Journal
CLINICAL NEUROPHARMACOLOGY
Volume 37, Issue 4, Pages 123-124Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WNF.0000000000000035
Keywords
aripiprazole; delayed sleep phase syndrome; histamine; insomnia; depression
Categories
Funding
- Grants-in-Aid for Scientific Research [25461731] Funding Source: KAKEN
Ask authors/readers for more resources
Delayed sleep phase syndrome (DSPS) comprises a persistent or recurrent pattern of sleep disturbances, sleep disruption that leads to insomnia and/or excessive daytime sleepiness, and impaired functioning in social, occupational, or other spheres. Aripiprazole (APZ), a second-generation antipsychotic, manifests a novel mechanism of action by serving as a partial agonist of both D2 and serotonergic 5-HT1A receptors and antagonist of 5-HT2A receptors. We have used APZ to treat DSPS. One reason it was effective may be that the insomnia induced by daytime APZ was effective in treating the patient's daytime sleepiness. Another reason may be APZ increases histamine release which controls sleep-wake cycles. Thus, APZ may be therapeutic for DSPS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available